Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
Manfredi Rizzo, Alessandro Colletti, Peter E. Penson, et al.
Pharmacological Research (2023) Vol. 189, pp. 106679-106679
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 454-499
Open Access | Times Cited: 30
Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
Hafiza Madiha Jaffar, Fahad Al‐Asmari, Faima Atta Khan, et al.
Food Science & Nutrition (2024) Vol. 12, Iss. 5, pp. 3097-3111
Open Access | Times Cited: 18
Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy?
Amirhossein Sahebkar, Zahra Foroutan, Niki Katsiki, et al.
Metabolism (2023) Vol. 146, pp. 155659-155659
Closed Access | Times Cited: 30
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Cristina Bică, Roxana Adriana Stoica, Teodor Salmen, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1136-1136
Open Access | Times Cited: 28
Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?
Kamila Kasprzak‐Drozd, Przemysław Niziński, Paulina Kasprzak, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3746-3746
Open Access | Times Cited: 12
NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics
Dimitris Kounatidis, Natalia G. Vallianou, Eleni Geladari, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 826-826
Open Access | Times Cited: 11
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 9
Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
Guocheng Rao, Xi Peng, Xinqiong Li, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 20
Extract of Silphium perfoliatum L. improve lipid accumulation in NAFLD mice by regulating AMPK/FXR signaling pathway
Jiyu Xu, Wenjing Jia, Guoying Zhang, et al.
Journal of Ethnopharmacology (2024) Vol. 327, pp. 118054-118054
Closed Access | Times Cited: 6
Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
Aneta Sokal, Sara Jarmakiewicz-Czaja, Katarzyna Ferenc, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5238-5238
Open Access | Times Cited: 6
The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects
Luana de Fátima Alves, J. Bernadette Moore, Douglas B. Kell
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 9082-9082
Open Access | Times Cited: 6
Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease
Hamza Elbouny, Ayoub Amssayef, Rania Benjamaa, et al.
Nutrire (2025) Vol. 50, Iss. 1
Closed Access
Remnant cholesterol and its variability independent of low density lipoprotein cholesterol predict metabolic dysfunction associated steatotic liver disease
Yuting Sun, Xinlei Miao, Manling Hu, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Pure total flavonoids from citrus alleviate oxidative stress and inflammation in nonalcoholic fatty liver disease by regulating the miR-137-3p/NOXA2/NOX2 pathway
Junbin Yan, Yunmeng Nie, Sumei Xu, et al.
Phytomedicine (2023) Vol. 118, pp. 154944-154944
Closed Access | Times Cited: 15
The Possible Role of Probiotic Supplementation in Inflammation: A Narrative Review
Alessandro Colletti, Marzia Pellizzato, Arrigo F.G. Cicero
Microorganisms (2023) Vol. 11, Iss. 9, pp. 2160-2160
Open Access | Times Cited: 15
The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, et al.
Journal of Diabetes and its Complications (2024) Vol. 38, Iss. 8, pp. 108780-108780
Closed Access | Times Cited: 4
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
Consolato Sergi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8462-8462
Open Access | Times Cited: 4
Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome”
Suleiman Al Ashi, Ali A. Rizvi, Manfredi Rizzo
Frontiers in Clinical Diabetes and Healthcare (2025) Vol. 5
Open Access
Web of Science‐Based Visualization of Metabolic Dysfunction‐Associated Fatty Liver Disease in Pediatric and Adolescent Populations: A Bibliometric Study
Liangyu Hu, Hongyin Du, Qianqian Zhou, et al.
Health Science Reports (2025) Vol. 8, Iss. 2
Open Access
Safety and Toxicity of Nutraceuticals: Concerns, Challenges and Global Regulatory Aspects
Pramod K. Prabhakar, Deepak Kumar Verma, Mamoni Banerjee
(2025), pp. 437-462
Closed Access
The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels
Alessandro Pezzoli, Ludovico Abenavoli, Marialaura Scarcella, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 387-387
Open Access
Epidemiological dynamics of burden and health inequalities in metabolic dysfunction-associated steatotic liver disease in adolescents at global, regional, and national levels, 1990-2021
Xiaohui Sui, Junde Zhao, Yuxin Yang, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102537-102537
Closed Access
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, et al.
Medicina (2023) Vol. 59, Iss. 10, pp. 1789-1789
Open Access | Times Cited: 9
Calenduloside E ameliorates non-alcoholic fatty liver disease via modulating a pyroptosis-dependent pathway.
Yifei Le, Jianan Guo, Zhijun Liu, et al.
Journal of Ethnopharmacology (2023) Vol. 319, pp. 117239-117239
Closed Access | Times Cited: 8
Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions
Theodora Metsovitis, Marco Bernardi, Éric Bruckert, et al.
Archives of Medical Science (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top